Featured products

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC7711	Losmapimod Featured	Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3.
DC2105	Lovastatin (MK-803) Featured	Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM, used for lowering cholesterol (hypolipidemic agent).
DC8066	Loxiglumide Featured	Loxiglumide is a Exogenous cholecystokinin (CCK-A) receptor antagonist, stimulates calorie intake and hunger feelings in humans.
DC22338	Larotrectinib (LOXO-101 free base) Featured	LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases.
DC9837	Larotrectinib (LOXO-101 sulfate) Featured	LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases.
DC11448	LOXO 195(Selitrectinib) Featured	LOXO-195 is a next-generation TRK kinase (TKI) inhibitor, with IC50s of 0.6±0.1 nM, <2.5 nM for TRKA and TRKC respectively.
DC10867	LP-211 Featured	LP-211 is a selective and blood−brain barrier penetrant 5-HT7 receptor agonist, with a Ki of 0.58 nM, with high selectivity over 5-HT1A receptor (Ki, 188 nM) and D2 receptor (Ki, 142 nM).
DC23403	LP99 Featured	LP99 is the first potent and selective BRD7/9 bromodomain inhibitor with Kd of 99 nM for BRD9.
DC20000	LR-90 Featured	LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes. LR-90 is also used in the research of diabetic animal model.
DC20086	LRE1 Featured	LRE1 is a specific and allosteric inhibitor of soluble adenylyl cyclase.
DC11440	LRRK2 inhibitor 18 Featured	LRRK2 inhibitor 18(Compound 18) is a potent azaindazole leucine-rich repeat kinase 2 (LRRK2) inhibitor with Ki of 4.1 nM.
DC8237	LRRK2-IN-1 Featured	LRRK2-IN-1 inhibits both wild-type and G2019S mutant LRRK2 kinase activity with IC50 values of 13 nM and 6 nM , respectively with 0.1 mM ATP in the assay.
DC8541	ORY-1001(Ladademstat) Featured	ORY-1001 dihydrochloride (RG-6016, Ladademstat) is a highly potent, selective inhibitor of lysine-specific demethylase KDM1A (LSD1) with IC50 of 18 nM, displays high selectivity for KDM1A over other FAD-containing monoamine oxidases.
DC21249	LSN 3213128 Featured	LSN 3213128 is a novel potent, selective and orally-bioavailable antifolate with potent and specific inhibitory activity for AICARFT.
DC7878	LSN2814617 Featured	LSN2814617 is a neurotoxic positive allosteric modulator.
DC10665	LSN3154567(Nampt-IN-1) Featured	LSN3154567 is a novel inhibitor of NAMPT with IC50 of 18 nM (NCI-H1155 cell), 49 nM (Calu-6 cell), 333 nM (HCC1937 cell), and 389 nM (MCF-7 cell), respectively.
DC26113	LSP4–2022 Featured	LSP4–2022 is a novel potent, selective, brain-penetrant mGluR4 agonist with EC50 of 0.11 uM in cell-based assays.
DC10755	LSZ-102 Featured	LSZ102 is a potent, orally bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
DC10072	LTI-291 Featured	LTI-291 is a Glucocerebrosidase (Gcase) activator for the treament of Parkinson's disease (PD).
DC10988	LTX-401 Featured	LTX-401 is a novel oncolytic amino acid derivative that specifically targets the Golgi apparatus, demonstrating significant potential in cancer therapy. In vitro studies reveal that LTX-401 effectively reduces the viability of various tumor cell lines, exhibiting cytotoxic activity across a range of concentrations. Notably, it shows the highest potency against the human malignant melanoma cell line MDA-MB-435S (IC50 = 13.5 μM) and the lowest activity against the human hepatocellular carcinoma cell line HEPG2 (IC50 = 35.4 μM). For other cell lines, the IC50 values fall within a narrow range of 19-32 μM. Importantly, LTX-401 does not induce hemolysis in red blood cells at concentrations effective for cancer cell death, with hemolytic activity only observed at much higher concentrations (400 μg/mL = 1087 μM). Additionally, LTX-401 demonstrates cytotoxicity against non-malignant cell lines, including HUV-EC-C endothelial cells, HaCat keratinocytes, and MRC-5 fibroblasts, suggesting a broad but selective mechanism of action.
DC7583	Idalopirdine(Lu-AE-58054) Featured	Lu AE58054 is an in-vitro potency and selectivity, in-vivo binding affinity and effect of the 5-HT(6)R antagonist with a Ki value of 0.83 nM.
DC9784	Lu AF21934 Featured	Lu AF21934 is a brain-penetrating positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu4),reduces the harmaline-induced hyperactivity
DC8287	Lubiprostone Featured	Lubiprostone(SPI-0211;RU0211) is a gastrointestinal agent used for the treatment of idiopathic chronic constipation.
DC23647	LUF7346 Featured	LUF7346 is a novel hERG allosteric modulator that slows IKr deactivation and positively shifting IKr inactivation.
DC8611	Luliconazole Featured	Luliconazole(NND 502) is an azole antifungal indicated for the topical treatment of interdigital tinea pedis.
DC22906	Lumateperone Featured	Lumateperone (ITI-007) is a potent 5-HT2A antagonist (Ki=0.54 nM), postsynaptic D2 antagonist(Ki=32 nM), and SERT blocker (Ki= 61 nM).
DC11422	Lumateperone Tosylate Featured	Lumateperone Tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a SERT blocker (Ki = 61 nM).
DC3173	Lurasidone HCl Featured	Lurasidone is an atypical antipsychotic, inhibits Dopamine D2, 5-HT2A, 5-HT7, 5-HT1A and noradrenaline α2C with IC50 of 1.68 nM, 2.03 nM, 0.495 nM, 6.75 nM and 10.8 nM, respectively.
DC9938	Lusutrombopag（S-888711） Featured	Lusutrombopag（S-888711） is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist being developed by Shionogi for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery.
DC20271	LUT014 Featured	LUT014 is a novel BRAF agonist.

Featured products

Customized Consultation X

Your information is safe with us. * Required Fields.